Home > Insider Trading > Filing (0001847903-23-000045)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1847903	Centessa Pharmaceuticals Plc	CNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1861878	Antoine Yver	C/O Centessa Pharmaceuticals Plc 3Rd Fl., 1 Ashley Rd, Altrincham Cheshire X0 WA14 2DT	Evp & Chairman Of Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2023-02-01	77,200	$0.00	821,381	No	4	A	Direct
Ordinary Shares	Disposition	2023-02-01	7,700	$3.79	813,681	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Share Option (right to buy)	Acquisiton	2023-02-01	115,000	$0.00	115,000	$3.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
115,000		2033-02-01	No	4	A	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024.
The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.7500 to $3.7950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.